LIVE WEBINAR: Tuesday, January 4, 2022, 5:00 PM – 6:00 PM Eastern Time (ET)

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Oncology

A Multitumor CME/MOC-Accredited Live Webinar Series

Follicular Lymphoma

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.


Join us on Tuesday, January 4th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty
Laurie H Sehn, MD, MPH
Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Clinical Professor of Medicine
Division of Medical Oncology
University of British Columbia
Associate Editor, Blood
Vancouver, British Columbia, Canada

Additional faculty to be announced.

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from Bristol-Myers Squibb Company and Genentech, a member of the Roche Group.

Tuesday, January 4, 2022
5:00 PM – 6:00 PM Eastern Time
Live CME/MOC-accredited webinar

Topics to Be Discussed

  • PART I: Optimizing Current Clinical Management Algorithms for Patients with Follicular Lymphoma
  • PART II: Novel and Investigational Agents and Strategies

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of follicular lymphoma (FL).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Evaluate published research data and clinical investigator perspectives when designing an optimal induction approach for patients with newly diagnosed FL requiring active therapy.
  • Identify patient- and disease-specific factors that may portend poor response to initial chemoimmunotherapy, and consider this information in decision-making for patients with previously untreated FL.
  • Appreciate available data evaluating rituximab/lenalidomide for patients with treatment-naïve or relapsed/refractory (R/R) FL, and optimally incorporate this therapeutic approach into management algorithms.
  • Compare and contrast data supporting the use of the commercially available PI3K inhibitors idelalisib, copanlisib, duvelisib and umbralisib to optimally integrate these agents into the care of patients with R/R FL.
  • Recognize the recent FDA approval of tazemetostat for R/R FL, and identify patients for whom treatment with this novel agent may be appropriate.
  • Recall key efficacy and safety data from clinical trials of approved and investigational chimeric antigen receptor T-cell therapies directed at CD19 for R/R FL, and identify patients who may be candidates for this approach.
  • Review the mechanism of action, available data and ongoing evaluation with bispecific antibodies targeting CD20 and CD3, and consider the potential role of these agents in the management of R/R FL.
  • Assess ongoing clinical trials evaluating other novel investigational approaches for newly diagnosed or R/R FL, and obtain consent from appropriate patients for study participation.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Bristol-Myers Squibb Company and Genentech, a member of the Roche Group.